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Methods: Epidemiological data from candidemia episodes were collected during 2006 in a large teaching hospital. Incidence was calculated by 1,000 admission and 1,000 patient days.
Minimal inhibitory concentrations (MIC) were determined using Sensititre Yeast-One Y8, and E-test. The following drugs were tested: amphotericin B (AMB); caspofungin (CAS); posaconazole (POS), fluconazole (FLU), Itraconazol (ITRA) and voriconazole (VOR). The disk diffusion method was also performed for FLU and VOR according to CLSI.
Results: One hundred and thirty-six cases of candidemia were identified and represented 3.5% of the overall positive blood cultures. Incidence was 1.87 cases per 1,000 admissions and 0.27 cases per 1,000 patient-days. 58.1% patients were male and the median age was 40 years old being cancer the most frequent associated underlying disease. C. albicans (52.2%), followed by C. parapsilosis (22.1%), C. tropicalis (14.8%) and C. glabrata (6.6%) were the more frequent species. Among 100 isolates viable for susceptibility tests 100% were susceptible to AMB (MIC 90 = 1.0 mg/L) and CAS (MIC 90 = 0.064 mg/L); 98% to VOR (MIC 90 = 0.008 mg/L); 91% to FLU (MIC90 = 0.5 mg/L); and 66% to ITRA (MIC 90 = 0.125 mg/L).
Posaconazole MIC90was 0.032 mg/mL. The percentage of essential agreement (EA) and categorical agreement (CA) between broth micro dilution and other methodologies were >93%, except for itraconazole (EA 80%, CA 70%). CA between Sensititre Yeast-One versus disk diffusion and E-test versus disk diffusion for FLU were respectively: (94%; 95%) and for VOR(96%,98%). Minor errors accounted for the majority of categorical errors.
Conclusion: Candidemia by C. albicans still the majority of episodes in our Hospital but non-albicans C species are a growing problem and its susceptibility should be closed monitored even though overall resistance still very low. Disk diffusion and E-test had good CA and may be an alternative methodology for routine Latin America laboratories. Methods: Numerator data were generated by surveying all HIV infected patients in Georgia during 2003-2008 years. A routine serum cryptococcal antigen screening was performed on 920 HIV-positive/AIDS patients by ELISA (Premier Meridian, Italy) to improve the prognosis of cryptococcal meningitis in HIV-infected patients through earlier diagnosis. The cerebrospinal fluid (CSF) samples were processed for ELISA testing after preliminary microscopic examination, comprising wet mount, Indian ink.
Results: Cryptococcal antigen was detected in the sera of 103 (11.2%) of them. Cerebrospinal fluid was obtained from 98 of these 103 patients and the presence of Cryptococcus neoformans was demonstrated by direct microscopy in 64 (66%) of them. This represents 7% of the originally screened HIV seropositive group. The incidence of cryptococcal isolation was in the 30-45 age group and predominantly affected were male patients (59 from 64).
Conclusion: In Georgia prevalence of Cryptococcal meningitis among HIV seropositive patients is about 7%. We found some relationship between age, gender and prevalence of Cryptococcal meningitis among HIV infected patients. The routine mycological surveillance is required for HIV/AIDS patients to help in an early diagnosis and appropriate therapy. 
